Lumen Bioscience Details 2022 Company and Facilities Growth, New Funding, and Clinical Pipeline Progress

by admin | Jan 5, 2023 | Press Release

-Progress across all commercial and charitable clinical research programs -Strong growth in headcount and facilities, including newly commissioned cGMP plant -$36 million in new funding in 2H2022, including major new research grants and equity Seattle, WA, January 5,...

Lumen Bioscience Receives Broad Funding Support for Advancement of Antibiotic Alternative for Preventing Traveler’s Diarrhea

by admin | Jan 4, 2023 | Press Release

Bill & Melinda Gates Foundation, Department of Defense and CARB-X Back Further Development of Spirulina-Based Therapeutics Seattle, WA, January 4, 2023 – Lumen Bioscience, a clinical-stage biotechnology company developing biologic drugs for highly prevalent...

Biotech industry leaders share cautious optimism for 2023 amid downturn and layoffs

by admin | Dec 27, 2022 | Press Release

Read more

Lumen Bioscience Awarded $3.6 Million by U.S. Army to Advance Low-cost, Scalable Preventative for Antibiotic-Resistant Infections

by admin | Dec 23, 2022 | Press Release

Program builds on Lumen’s leading position in the development of complex biologic drug cocktails Seattle, WA, December 23, 2022 – Lumen Bioscience—a clinical-stage biopharmaceutical company developing biologic drugs for highly prevalent diseases—today announced the...

BARDA-funded Intranasal Antibody Cocktail for COVID-19 Shows Promise in a Preclinical Study

by admin | Dec 20, 2022 | Press Release

Administration of LMN-301 pre- and post-viral challenge associated with improved clinical outcomes Seattle, WA, December 20, 2022 – Lumen Bioscience — a clinical stage biopharmaceutical company developing biologic drugs for highly prevalent diseases — announced today...